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with the Severity of Ocular Disease in Autoimmune
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Claudio P. Juarez,3 Jose´ D. Luna,3 and Gabriel A. Rabinovich1
PURPOSE. Galectin (Gal)-1, an endogenous lectin found at sites
of immune privilege, plays a critical role in the regulation of
the immune response. Therapeutic administration of Gal-1 or
its genetic delivery suppresses chronic inflammation in exper-
imental models of autoimmunity. The purpose of this work
was to investigate the occurrence of circulating anti-Gal-1 an-
tibodies in patients with autoimmune and infectious uveitis as
potential determinant factors of disease progression.
METHODS. IgG, IgE, and IgA anti-Gal-1 antibodies were assessed
by ELISA and Western blot in sera from patients with autoim-
mune (n  47) and infectious (n  15) uveitis compared with
healthy control subjects (n  30). The frequency of anti-Gal-1
antibodies was examined in patients experiencing poor clinical
outcome (n  21) or good evolution (n  9). Anti-Gal-1
antibodies were eluted by incubating patient sera with nitro-
cellulose filters adsorbed with rGal-1. The ability of these anti-
bodies to recognize retinal tissue was assessed by ELISA, West-
ern blot, and immunohistochemistry.
RESULTS. IgE, IgG, and IgA anti-Gal-1 antibodies were increased
in sera from patients with autoimmune uveitis (P  0.001 vs.
controls) and toxoplasmic retinochoroiditis (P  0.001). The
level of anti-Gal-1 IgE and IgG antibodies was associated with
progressive disease and poor outcome in autoimmune and
infectious uveitis. Furthermore, these antibodies strongly im-
munoreacted with retinal lysates and recognized retinal struc-
tures mainly photoreceptors in retinal sections.
CONCLUSIONS. Anti-retinal Gal-1 antibodies are present in sera
from patients with uveitis and can be associated with the
progression of ocular disease, suggesting their potential use in
follow-up observations of these patients. (Invest Ophthalmol
Vis Sci. 2006;47:1550–1556) DOI:10.1167/iovs.05-1234
Intraocular inflammatory diseases are a major cause of severeimpairment, accounting for 10% of blind registrations in the
working population.1,2 These uveitic syndromes may occur as
autoimmune or infectious processes, which are typically char-
acterized by inflammation and subsequent destruction of the
neural retina.1–3 How the inflammatory process is initiated is
still not clear, but current knowledge indicates that subversion
of immune privilege mechanisms by autoimmune insults and
pathogens may play a critical role.3 In this context, it has been
demonstrated that apoptotic cell death promotes immune priv-
ilege within the ocular microenvironment and contributes to
amelioration and clinical resolution of autoimmune uveitis
(AU).3,4 Furthermore, it has been speculated that specific
blockade of immunosuppressive factors in the ocular microen-
vironment contributes to the initiation and perpetuation of
Th1-mediated inflammation.3
Galectin (Gal)-1, a member of a highly conserved protein
family,5,6 is expressed at sites of immune privilege such as the
eyes and testis7–10 and has the potential to regulate immune
tolerance and inflammation.11–19 How Gal-1 exerts its anti-
inflammatory response is poorly understood, primarily because
of its pleiotropic nature where it has been shown to suppress
T-cell activation,20 T-cell adhesion to extracellular matrix,21
and Th1 cytokine secretion.11,16–18 Foremost, however, has
been the ability of Gal-1 to promote T-cell apoptosis through
binding to specific cell surface glycoconjugates.13–18 In this
context, Ishida et al.8 have recently reported the ability of
retinal pigment epithelium to suppress T-cell activation in vitro
through secretion of Gal-1, suggesting the potential role of this
protein in the establishment of immune privilege.8
We have recently shown that Gal-1 plays a critical role in
the maintenance and re-establishment of immune tolerance in
experimental models of chronic inflammation and cancer.11,12
Taken together, these observations led us to speculate that
specific blockade of immunosuppressive Gal-1 may contribute
to the breakdown of immune privilege and to the perpetuation
of the inflammatory response. In the present study, we deter-
mined the occurrence of IgG, IgA, and IgE anti-Gal-1 antibodies
in sera from patients with AU or IU and posed the question of
whether these autoantibodies recognize retinal structures and
play a role in the immunopathogenesis of human uveitis.
MATERIALS AND METHODS
Antibodies and rGal-1 Preparation
Peroxidase-conjugated goat anti-human IgG; peroxidase-conjugated
goat anti-human IgA; alkaline-phosphatase-conjugated goat anti-human
IgE; goat anti-human IgG, IgA, and IgE and peroxidase-conjugated
anti-goat IgG were purchased from Sigma-Aldrich (St. Louis, MO).
Anti-human Gal-1 polyclonal antibody was obtained as previously de-
scribed.12 This antibody was highly specific for Gal-1, because it did
not recognize other members of the galectin family, such as Gal-3.22
Human rGal-1 was produced and purified as described.23
From the 1Divisio´n Immunogene´tica, Facultad de Medicina, Uni-
versidad de Buenos Aires, Buenos Aires, Argentina; the 2Laboratorio of
Inmunopatologı´a LIIDO, Co´rdoba, Argentina; the 3Fundacio´n Ver, Co´r-
doba, Argentina; and the 5Divisio´n Medicina III, Facultad de Ciencias
Me´dicas, Universidad Nacional de Co´rdoba, Argentina.
4Contributed equally to the work and therefore should be consid-
ered equivalent authors.
Supported by the Mizutani Foundation for Glycosciences (Japan),
Grant PICT 2003-05-13787 from the Agencia de Promocio´n Cientı´fica y
Tecnolo´gica (Argentina), Grant M091 from the University of Buenos
Aires, the Wellcome Trust (UK), and the Fundacio´n Sales (Argentina).
Submitted for publication September 16, 2005; revised November
18, 2005; accepted January 19, 2006.
Disclosure: M.D. Romero, None; J.C. Muin˜o, None; G.A. Bi-
anco, None; M. Ferrero, None; C.P. Juarez, None; J.D. Luna, None;
G.A. Rabinovich, None
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be marked “advertise-
ment” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Gabriel A. Rabinovich, Divisio´n Inmuno-
gene´tica, Hospital de Clı´nicas “Jose´ de San Martı´n,” Facultad de Medi-
cina, Universidad de Buenos Aires, Av. Co´rdoba 2351, 3er Piso
(C1120)Ciudad de Buenos Aires, Argentina; gabyrabi@ciudad.com.ar.
Investigative Ophthalmology & Visual Science, April 2006, Vol. 47, No. 4
1550 Copyright © Association for Research in Vision and Ophthalmology
Preparation of Bovine Retinal Cell Lysates
Retina was obtained from fresh bovine eyes, and extracts were pre-
pared by homogenizing retina in cold PBS containing 50 mM Tris-HCl,
150 mM NaCl, 1% NP-40, 10 mM EDTA, and protease inhibitor cocktail
(Sigma-Aldrich) and kept for 30 minutes on ice. The solution was
centrifuged at 4°C for 20 minutes at 10,000g, and the supernatants
were collected and stored at 20°C.
Patients
We studied 62 patients with uveitis, 32 males and 30 females (mean
age, 36.9  14.9 years; range, 5–72). The diagnosis of uveitis was
established according to clinical criteria as described.2,24 These pa-
tients with uveitis were treated for 3 months with methylprednisolone
in decreased immunosuppressive doses from 120 mg/d to 10 mg on
alternating days. In cases of poor response to treatment, patients were
included in a tacrolimus protocol in a dose of 5 mg/d for at least 1 year
of treatment. Patients were classified according to their clinical evolu-
tion in subgroups of severe relapsing uveitis with poor evolution and
uveitis with good evolution.
According to the etiology of uveitis, patients were classified as
previously described24 into the following groups: patients with AU
(n  47; 27 males and 20 females) and patients with IU, (n  15; 5
males and 10 females). Sera from age-matched healthy individuals (n
30) were used as the control. Patients with progressive disease were
clinically characterized by poor response to tacrolimus treatment, with
continuous crisis of uveitis and severe impairment of visual function,
whereas patients with good evolution responded successfully to treat-
ment with improvement of vision or only slight vision impairment.
Thirty patients treated with similar drug protocols with progressive
(n  21) and good (n  9) evolution were selected for longitudinal
analysis of anti-Gal-1 antibodies, which were determined at different
times (approximately every 6 months) during the course of the disease.
The studies were approved by the Institutional Review Board of the
Hospital de Clı´nicas Jose´ de San Martı´n and The Ethics Committee of
Fundacio´n Ver and complied with the tenets of the Declaration of
Helsinki.
Immunoadsorption
To examine the potential cross-reactivity between Gal-1 and retinal
tissue, immunoadsorption assays were performed as described by
Giordanengo et al.25 Briefly, rGal-1 (5 g/mL) was adsorbed to nitro-
cellulose filters. After adequate washing and blocking, filters were
incubated overnight at 4°C with 1:40 dilution of sera from 13 patients
with uveitis or 7 healthy control subjects. Bound antibodies were then
eluted with 0.02 M glycine pH 2.8 and neutralized with 1 M Tris-HCl
(pH 8.6). Each eluted sample was tested against rGal-1 (5 g/mL) and
bovine retinal tissue (50 g/mL) by ELISA and Western blot.
Enzyme-Linked Immunosorbent Assay
Serum levels of anti-Gal-1 IgE, IgG, and IgA antibodies were determined
by ELISA in sera from patients with uveitis or healthy control subjects.
Anti-Gal-1 antibodies recognizing rGal-1 or bovine retina were also
determined by ELISA in eluted material obtained from uveitis or control
sera. Briefly, microtiter plates (Nunc, Rochester, NY) were coated with
5 g/mL human rGal-1 in PBS, blocked, and incubated with a 1:100
dilution of human sera. Bound IgG and IgA were detected by incuba-
tion with peroxidase-conjugated goat anti-human IgG (1:1000) or per-
oxidase-conjugated goat-anti human IgA (1:1000), followed by sub-
strate (orthophenilendiamine). Bound IgE was detected with a 1:5000
dilution of alkaline phosphatase-conjugated goat anti-human IgE fol-
lowed by substrate (dinitrophenylphosphate). Optical densities were
measured at 490 or 405 nm respectively in an ELISA reader (Bio-Rad,
Richmond, CA). A serially diluted polyclonal rabbit anti-human Gal-1
antibody revealed with a peroxidase-conjugated anti-rabbit IgG was
used as a positive control for immunoreactivity. A result was consid-
ered positive if optical density was two or more standard deviations
above the mean of normal control sera.
Western Blot Analysis
SDS-PAGE was performed in an electrophoresis apparatus (Mini Prote-
an-II; Bio-Rad) as described.12 To assess the presence of anti-Gal-1
antibodies in patient sera, we resolved rGal-1 (5 g) and bovine retinal
lysates (30 g) on a 15% polyacrylamide gel. After electrophoresis, the
separated proteins were transferred onto nitrocellulose membranes
and probed with appropriate dilutions of human sera or eluted anti-
bodies from patients with uveitis or healthy control subjects. Blots
were then incubated with goat anti-human IgG, IgA, and IgE (1:100)
followed by peroxidase-conjugated anti-goat IgG (1:500) and devel-
oped using enhanced chemiluminescence (GE Healthcare, Piscataway,
NJ), and the films were analyzed (Image Analysis software; Scion,
Frederick, MD).
Immunohistochemistry
Semithin sections (0.5 m) of human eyes obtained for autopsies were
blocked with H2O2 followed by incubation with an adequate dilution
of rabbit anti-human Igs for 20 minutes at room temperature and then
incubated for 24 hours at 4°C with anti-Gal-1 antibodies eluted from
sera corresponding to patients with uveitis or healthy control subjects.
Incubation with optimal dilutions of goat anti-human IgG and IgE was
performed for 2 hours at room temperature. The reaction was com-
pleted by incubation with peroxidase-conjugated anti-goat IgG. All
reactions were revealed using bisdiaminobenzidine-H2O2 and visual-
ized by microscope (Olympus, San Diego, CA).
Statistical Analysis
Statistical analysis was performed by ANOVA for continuous variables
and 2 statistics for categorical variables. All tests for significance were
two-sided (Microstat-Ecosoft Inc., Indianapolis, IN). P  0.05 was
considered statistically significant.
RESULTS
Prevalence of Circulating Anti-Gal-1 Antibodies in
Sera from Patients with AU or IU
A quantitative determination of anti-Gal-1 antibodies was per-
formed by indirect ELISA in sera from patients with uveitis
(n  62) and healthy control subjects (n  30). As shown in
Figure 1A, Gal-1 immunoreactivity was detected in 80.6% of
patients with uveitis compared with 16.6% of healthy control
subjects (P 0.001). To determine whether anti-Gal-1 antibod-
ies occur in uveitis of different etiology, we classified patients
according to their clinical features as having AU or IU. In
addition, the last group was subdivided into toxoplasmic reti-
nochoroiditis (TR), tuberculosis uveitis (TU), and bacterial en-
dophthalmitis (BE). The prevalence of anti-Gal-1 antibodies in
each group is shown in Figure 1B.
Frequency of Different Anti-Gal-1 Antibody
Isotypes in Patients with AU or IU
The next issue we attempted to elucidate was related to spe-
cific anti-Gal-1 antibody isotypes present in sera from patients
with uveitis. Therefore, anti-Gal-1 IgG, IgA, and IgE isotypes
were investigated by ELISA in sera from patients with uveitis
(Fig. 1C). The highest percentage of immunoreactive sera in
the whole uveitic population corresponded to the IgE isotype
in 30 of 62 cases (48.4%), followed by IgG in 27 of 62 cases
(43.5%), whereas the lower frequency was found to be associ-
ated with the IgA isotype in 21 of 62 cases (33.9%). In addition,
sera from control subjects were positive in 2 of 30 cases (3.3%)
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for IgE and IgG (P  0.001; IgE-, IgG-, and IgA-positive uveitis
sera versus the control). These findings were confirmed by
Western blot analysis of sera from different patients with AU
compared with sera from control individuals (Fig. 1D).
We then determined the percentages of different isotypes in
patients with uveitis by discriminating the ocular disease into
AU or IU. As shown in Figure 1E, all anti-Gal-1 isotypes were
significantly increased in patients with AU and TR (P  0.001
AU and TR versus control group; P  0.05 BE versus control
group for all isotypes tested). Furthermore, distinct levels of
IgG, IgA, and IgE anti-Gal-1 antibodies were present in the
different subgroups of AU and IU (Fig. 2).
IgG and IgE anti-Gal-1 Antibodies and the
Progression and Severity of Ocular Inflammation
in Patients with Uveitis
To determine whether anti-Gal-1 antibodies could be associ-
ated with the evolution of ocular disease in patients with AU or
IU, we investigated the possible relationship between the lev-
els of IgG, IgE, and IgA anti-Gal-1 antibodies and clinical man-
ifestations in patients with progressive (n 21) and good (n
9) evolution treated under similar drug protocols. Levels of
specific antibodies were determined during the course of the
disease. Longitudinal analysis is shown in two representative
age-matched polar cases with either progressive (Fig. 3A) or
good evolution (Fig. 3B) in samples collected approximately
every 6 months. The patient with progressive disease was
clinically characterized by poor response to tacrolimus treat-
ment, continuous uveitis crises, and the persistent presence
of anti-Gal-1 IgE antibodies. This patient was blind in one
eye, and the second eye displayed continuous and persistent
clinical manifestations of uveitis (Fig. 3A). In contrast, the
second patient responded to treatment with improvement
of vision, and this clinical outcome was associated with a
decrease in the levels of anti-Gal-1 IgE antibodies (Fig. 3B).
Thus, the levels of IgE anti-Gal-1 antibodies positively cor-
relate with the severity of inflammatory disease and poor
clinical evolution during the course of the ocular inflamma-
tory disease.
FIGURE 1. Anti-Gal-1 antibodies in
sera from patients with AU or IU. (A)
Percentages of immunoreactive sera
from patients with uveitis (n  62)
compared with control sera (n 30;
P  0.0.001). Reactivity was consid-
ered positive if optical density (OD)
was two or more standard deviations
above the mean of normal values.
(B) Percentages of immunoreactive
sera from patients with uveitis dis-
criminating between AU (n  47),
TR (n  4), TU (n  3), BE (n  8),
and control subjects (n  30; P 
0.001 AU and TR versus control). (C)
Percentages of sera showing IgG,
IgA, and IgE reactivity against rGal-1
in patients with uveitis (P  0.001
versus control for all isotypes
tested). (D) IgG-, IgA-, and IgE-immu-
noreactive profiles by Western blot
of representative sera from patients
with uveitis and control subjects. (E)
Percentages of sera exhibiting posi-
tive IgG, IgA, and IgE immunoreac-
tivity in different subgroups of pa-
tients with uveitis and control
subjects (P  0.001 AU and TR ver-
sus the control for all isotypes tested;
P 0.05 BE versus the control for all
isotypes tested).
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Circulating Anti-Gal-1 Antibodies in Bovine
and Human Retina
To gain insight into the functional significance of anti-Gal-1
antibodies present in sera from patients with uveitis, we ex-
plored whether these antibodies may specifically recognize
retinal structures. For this purpose, nitrocellulose filters were
coated with human rGal-1 and exposed to sera from selected
patients with uveitis (n  13) and control subjects (n  7).
Bound antibodies were specifically eluted as described in the
Materials and Methods section. Anti-Gal-1 IgG antibodies were
detected by ELISA in nine of the eluted fractions (Fig. 4A), six
of which strongly reacted with bovine retinal lysates (Fig. 4B).
In contrast, IgE anti-Gal-1 antibodies were detected in nine of
the eluted fractions (Fig. 4A), all of which immunoreacted with
bovine retinal lysates (Fig. 4B). Finally, IgA anti-Gal-1 antibodies
were detected in four of the eluted fractions (Fig. 4A), but only
one fraction reacted against bovine retina (Fig. 4B). No signs of
immunoreactivity against rGal-1 or bovine retina were detected
using fractions eluted from control sera (data not shown).
To confirm these findings, we analyzed IgG immunoreactiv-
ity of eluted fractions by Western blot. Figures 4C and 4D show
the immunoreactive profile of eluted anti-Gal-1 antibodies from
two representative sera with high immunoreactivity against
rGal-1 (Fig. 4C; lanes 2 and 3) and bovine retinal lysates (Fig.
4D; lanes 2 and 3). Controls using the rabbit anti-Gal-1 poly-
clonal antibody are shown in Figures 4C and 4D (lane 1).
To determine whether the circulating anti-Gal-1 antibodies
can recognize specific retinal structures, sections of human
retinal tissue were exposed to eluted antibodies. As shown in
Figures 4E and 4F, anti-Gal-1 antibodies eluted from sera from
patients with AU demonstrated widespread immunostaining
along all retinal layers, particularly at the level of photorecep-
tors (Figs. 4E, 4F for IgG and IgE, respectively). Eluted anti-
Gal-1 antibodies preadsorbed with rGal-1 were used as the
control for specificity and did not show any immunoreactivity
(Figs. 4E, 4F, insets). As expected, eluted material from control
individuals did not show significant immunoreactivity against
retinal sections (Figs. 4G, 4H for IgG and IgE, respectively).
DISCUSSION
Uveitis is a generic term that encompasses a variety of intraocular
inflammatory responses of infectious or autoimmune origin.1–3
Despite considerable progress in elucidating the immunopatho-
genesis of these ocular disorders, there is still scarce information
about reliable immunologic markers of disease evolution.26 In this
context, no significant differences in the levels of anti-retinal IRBP
antibodies were detected between sera from patients with uveitis
and healthy control subjects,26 although evidence has been dem-
onstrated regarding the presence of IgG and IgE autoantibodies to
retinal S antigen in patients with uveitis.24
In the present study, we report the occurrence of anti-Gal-1
antibodies in sera from patients with AU or IU compared with
healthy control subjects. Of note, the frequency and levels of
anti-Gal-1 IgE antibodies correlated with poor evolution of
FIGURE 2. Anti-Gal-1 IgG, IgA, and IgE isotypes in subgroups of pa-
tients with AU or IU. The AU group was subdivided into acute recur-
rent iridocyclitis (ARI), Eales’ diseases (ED), pars planitis (PP), unilat-
eral multifocal choroiditis (UMC), bilateral multifocal choroiditis
(BMC), idiopathic chronic unilateral recurrent iridocyclitis (ICURI),
and idiopathic chronic bilateral recurrent iridocyclitis (ICBRI). Cases of
IU were subdivided into TU, BE, and TR. Results were considered
positive if optical density (OD) was two or more standard deviations
above the mean in the control group (cutoff).
FIGURE 3. Anti-Gal-1 antibodies are
associated with progression and
poor outcome in patients with uve-
itis. Longitudinal analysis of anti-
Gal-1 antibodies (ELISA) was per-
formed in two polar representative
sera from age-matched patients with
progressive disease (A) or good evo-
lution (B). Both patients were
treated in the same protocols. A total
of 21 sera samples from patients
with uveitis who had progressive dis-
ease and 9 from patients with good
evolution were analyzed and had
profiles comparable to those shown.
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ocular inflammatory disease in patients with uveitis. IgE and
IgG anti-Gal-1 antibodies specifically immunoreacted with
Gal-1 in retinal cell lysates and recognized retinal structures,
mainly photoreceptors, in sections of human retinal tissue.
Some alternative nonexclusive hypotheses could be postu-
lated to explain the increased frequency of anti-Gal-1 antibod-
ies in inflammatory ocular disorders. First, the occurrence of
these antibodies might be a direct consequence of the release
of tissue-associated Gal-1 during the inflammatory response
accompanying the ocular disease. However, these anti-Gal-1
antibodies could also appear in response to autoimmune or
infectious insults and may contribute to the breakdown of
immune tolerance and privilege by blocking functionally active
sites of retina-associated Gal-1.
FIGURE 4. Immunoreactivity of anti-
Gal-1 antibodies against retinal tis-
sue. Eluted anti-Gal-1 antibodies
from patients’ sera were assayed
against rGal-1 (A, C) and retinal ly-
sates (B, D) by ELISA (A, B) and
Western blot (C, D). IgG, IgA, and
IgE isotypes were determined by
ELISA, and IgG immunoreactivity
was confirmed by Western blot.
(E–H) Sections of human retina were
exposed to anti-Gal-1 antibodies
eluted from sera of patients with
uveitis (E, F) or healthy control sub-
jects (G, H). Bound antibodies were
detected using peroxidase-labeled
goat anti-human IgG (E, G) and IgE
(F, H). Arrow: photoreceptors layer
(Ph). Eluted antibodies preadsorbed
with rGal-1 were used as the immu-
noreactivity control (insets).
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Because of its ability to inhibit T-cell effector functions, it
has been speculated that endogenous Gal-1 expression in the
eye7–9 could function as a novel mechanism of immune privi-
lege. In the mammalian retina, Gal-1 is preferentially expressed
by the retinal pigment epithelium, photoreceptors, and the
outer limiting membrane.7 Ishida et al.8 demonstrated that cells
from retinal pigment epithelium suppress T-cell activation, at
least in part, through Gal-1-mediated mechanisms. Accord-
ingly, we hypothesize that Gal-1 may also be secreted to the
aqueous humor as an immunosuppressive cytokine,4 where it
may endow T cells with the capacity to regulate the inflamma-
tory response. This hypothesis, which warrants further inves-
tigation, is consistent with our recent findings demonstrating
that Gal-1 suppresses experimental autoimmune retinal disease
in a murine model by promoting a shift toward a T-regulatory
response (Rabinovich et al., manuscript submitted).
To counteract inflammation, the eye is confined to an im-
munosuppressive microenvironment that uses multiple mech-
anisms to suppress the activation and cytotoxic activity of T
cells.3 Some of these mechanisms involve soluble factors found
in aqueous humor, which suppress the generation of patho-
genic effector T cells and the production of proinflammatory
cytokines.3 In this context, the presence of anti-Gal-1 antibod-
ies recognizing retinal structures may play a potential role in
blocking the immunoregulatory activity of this protein and
promoting an increased survival of pathogenic T cells.
In addition to the potential impact of these antibodies in the
modulation of immune tolerance, anti-retinal Gal-1 antibodies
may also have implications in the modulation of retinal archi-
tecture. In this regard, Uehara et al.7 reported retinal detach-
ment and vacuolation of the outer plexiform layer when an
anti-Gal-1 antibody was injected intravitreously in rat eyes,
suggesting that endogenous Gal-1 may also be involved in the
adhesion of photoreceptors and outer plexiform layers by
interacting with specific glycoconjugates.7 Accordingly, in the
present study, sera from patients with AU showed high levels
of specific IgE and IgG anti Gal-1 antibodies that were found to
be clinically associated with severe impairment and loss of
vision. It is noteworthy that IgE was the most frequently de-
tected isotype in sera from patients with poor clinical outcome
and that patients with good evolution did not show IgE immu-
noreactivity. The occurrence of high levels of IgE autoantibod-
ies in autoimmune disorders has been reported in clinical
settings and experimental models, including uveitis, thyroid-
itis, and chemically induced autoimmunity.24,27–29 However,
the role of IgE in the development and/or perpetuation of
autoimmune response remains to be elucidated.
The occurrence of anti-Gal-1 antibodies has been described
in inflammatory and neurologic processes,30 including acute
and chronic stages of Trypanosoma cruzi infection.25 In this
regard, we found in the present study that a greater proportion
of anti-Gal-1 antibodies observed in patients with IU corre-
sponds to infections caused by the protozoan Toxoplasma
gondii. This observation is worthy of discussion in terms of
previous findings describing the presence of a galactose-bind-
ing protein (with significant amino acid sequence homology to
Gal-1) in tachyzoites of a virulent T. gondii strain.31 In this
sense, it should be emphasized that TR is different from other
types of IU in that it is strikingly similar to AU. We and other
investigators recently highlighted the importance of autoanti-
bodies against retinal antigens in determining disease severity
in toxoplasmosis uveitis.24,32 In this regard, we have demon-
strated in an experimental model of arthritis induced by T.
gondii the presence of autoantibodies against retinal S antigen,
iris antigens, type-II collagen, and proteoglycans, which posi-
tively correlated with clinical manifestations of arthritis and
iridocyclitis.33 In addition, autoantibodies against other mem-
bers of the galectin family (Gal-3 and Gal-9) have been detected
in physiological and pathologic settings, including colon carci-
noma, Crohn’s disease and systemic lupus erythematosus.34–37
In conclusion, our results highlight the clinical importance
of specific anti-retinal Gal-1 antibodies in sera from patients
with AU or IU, indicating their potential prognostic use in
follow-up observation of inflammatory ocular diseases.
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